Literature DB >> 4719672

Heterogeneity of parathyroid hormone. Clinical and physiologic implications.

R Silverman, R S Yalow.   

Abstract

When immunoreactive human parathyroid hormone (hPTH), extracted by three different solvents (20% acetone in 1% acetic acid, 8 M urea, or normal saline) from parathyroid glandular tissue was subjected to Sephadex G-100 gel filtration and immunoassay using two different antisera (273 and C-329), four distinct fractions were observed. The first (I), a void volume peak, was detected by both antisera with similar immunoreactivity, as was a second (II), which had the elution and sedimentation properties of highly purified bovine parathyroid hormone (bPTH); a third (III) eluted between [(125)I]growth hormone and [(125)I]insulin, sedimented with the velocity of a molecule of approximately 6,000 mol wt, and was detected primarily by antiserum 273; a final fraction (IV), detected primarily by C-329, eluted just prior to [(125)I]insulin. The elution profiles of the acetone-acetic acid and 8 M urea extracts were similar and contained fraction II as their major component. In saline extracts, however, fraction III predominated. Three fractions, having gel filtration and immunologic characteristics similar to fractions II, III, and IV, respectively, of saline glandular extracts, were detected in the plasma of patients with both primary (adenomatous or carcinomatous) and secondary hyperparathyroidism. The predominant component in every plasma was the intermediate fraction that, like III, was detected primarily by antiserum 273, while the least abundant form was consistently the final fraction, detected primarily by antiserum C-329. The first fraction, like II, was detected with about equal potency by both antisera and had an elution volume on Sephadex corresponding to that of intact bPTH. It bore a reciprocal relationship to serum calcium and disappeared from the plasma of a uremic patient during calcium infusion or following parathyroidectomy with a half-time of no more than 20 min. This component therefore probably represents biologically active hormone. The intermediate and final fractions had turnover times in the plasma of a uremic patient more than 100 times greater than the active form, remained elevated even in the presence of post-parathyroidectomy hypoparathyroidism in this patient and were presumed to be biologically inactive. The ratio of biologically inactive fragments to the active form was greater in secondary hyperparathyroidism. The evidence presented favors a glandular origin for the fragments. Comparison of hormonal assays with the two antisera reveals a striking advantage in the preoperative diagnosis of primary hyperparathyroidism with antiserum 273 that is due to the enhanced sensitivity occasioned by its detection of a biologically inactive as well as the biologically active hormonal form.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4719672      PMCID: PMC302478          DOI: 10.1172/JCI107380

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  "Big, big insulin".

Authors:  T S Yalow; S A Berson
Journal:  Metabolism       Date:  1973-05       Impact factor: 8.694

3.  Separation of antibody-bound and unbound peptide hormones labelled with iodine-131 by talcum powder and precipitated silica.

Authors:  G Rosselin; R Assan; R S Yalow; S A Berson
Journal:  Nature       Date:  1966-10-22       Impact factor: 49.962

4.  Proparathyroid hormone: identification of a biosynthetic precursor to parathyroid hormone.

Authors:  B Kemper; J F Habener; J T Potts; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

5.  Proparathyroid hormone: biosynthesis by human parathyroid adenomas.

Authors:  J F Habener; B Kemper; J T Potts; A Rich
Journal:  Science       Date:  1972-11-10       Impact factor: 47.728

6.  Isolation of human parathyroid hormone.

Authors:  J L O'Riordan; J T Potts; G D Aurbach
Journal:  Endocrinology       Date:  1971-07       Impact factor: 4.736

7.  Human parathyroid gland immunoreactive peptides--evidence for proparathormone.

Authors:  E T Wong; A W Lindall; A L Schultz
Journal:  J Lab Clin Med       Date:  1971-11

8.  Determination of molecular weights and frictional ratios of proteins in impure systems by use of gel filtration and density gradient centrifugation. Application to crude preparations of sulfite and hydroxylamine reductases.

Authors:  L M Siegel; K J Monty
Journal:  Biochim Biophys Acta       Date:  1966-02-07

9.  Further studies on the nature of immunoreactive gastrin in human plasma.

Authors:  R S Yalow; S A Berson
Journal:  Gastroenterology       Date:  1971-02       Impact factor: 22.682

10.  Calcemic fraction-A: biosynthetic peptide precursor of parathyroid hormone.

Authors:  D V Cohn; R R Macgregor; L L Chu; J R Kimmel; J W Hamilton
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

View more
  41 in total

1.  Diagnosis and treatment of primary hyperparathyroidism.

Authors:  M A Dambacher; U Binswanger; J A Fischer
Journal:  Urol Res       Date:  1979-09

Review 2.  Intact parathyroid hormone assays.

Authors:  F C Logue; G H Beastall; W D Fraser; D S O'Reilly
Journal:  BMJ       Date:  1990-01-27

3.  Metabolism of bovine parathyroid hormone. Immunological and biological characteristics of fragments generated by liver perfusion.

Authors:  J M Canterbury; L A Bricker; G S Levey; P L Kozlovskis; E Ruiz; J E Zull; E Reiss
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

4.  Metabolism and biological activity of parathyroid hormone in renal cortical membranes.

Authors:  D Goltzman; A Peytremann; E N Callahan; G V Segre; J T Potts
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

5.  Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease.

Authors:  K A Hruska; R Kopelman; W E Rutherford; S Klahr; E Slatopolsky; A Greenwalt; T Bascom; J Markham
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

6.  Degradation of parathyroid hormone and fragment production by the isolated perfused dog kidney. The effect of glomerular filtration rate and perfusate CA++ concentrations.

Authors:  K A Hruska; K Martin; P Mennes; A Greenwalt; C Anderson; S Klahr; E Slatopolsky
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

7.  Selective uptake of the synthetic amino terminal fragment of bovine parathyroid hormone by isolated perfused bone.

Authors:  K J Martin; J J Freitag; M B Conrades; K A Hruska; S Klahr; E Slatopolsky
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

8.  Selective uptake of intact parathyroid hormone by the liver: differences between hepatic and renal uptake.

Authors:  K Martin; K Hruska; A Greenwalt; S Klahr; E Slatopolsky
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

9.  Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism.

Authors:  R C Benson; B L Riggs; B M Pickard; C D Arnaud
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog.

Authors:  J M Canterbury; S Lerman; A J Claflin; H Henry; A Norman; E Reiss
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.